RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Isavuconazole Effective in UncCAs and HMs
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 14
OP 16
DO 10.1177/155989771428008
UL http://mdc.sagepub.com/content/14/28/14.abstract
AB Patients with invasive fungal disease and comorbid conditions such as hematologic malignancy and uncontrolled malignancy were successfully treated with the novel triazole antifungal agent isavuconazole, regardless of minimum inhibitory concentrations required by baseline Aspergillus spp isolates. This article presents data according to type of malignancy from the Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis trial [SECURE; NCT00412893].